ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 952,47
0,48%
Dow Jones
38 651,23
1,11%
DAX
17 993,69
0,49%
Brent Oil
83,275
-0,42%
Bitcoin
61 614,63
4,22%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. SpringWorks Therapeutics Inc (SWTX)

  7. SpringWorks Therapeutics Inc (SWTX) Actualités

SWTX SpringWorks Therapeutics Inc

44,50
1,15 (2,65%)
Dernière mise à jour : 17:31:40
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
SpringWorks Therapeutics Inc SWTX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
1,15 2,65% 44,50 17:31:40
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
44,09 42,12 45,10 43,35
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
02/5/202412:30GLOBESpringWorks Therapeutics Reports First Quarter 2024..
24/4/202419:31GLOBESpringWorks Therapeutics Announces Abstracts Accepted for..
18/4/202413:00GLOBESpringWorks Therapeutics to Report First Quarter 2024..
04/3/202412:30GLOBESpringWorks Therapeutics Initiates Rolling Submission of New..
01/3/202423:16EDGAR2Form 144 - Report of proposed sale of securities
29/2/202414:30GLOBESpringWorks Therapeutics Announces European Medicines Agency..
27/2/202414:28EDGAR2Form 8-K - Current report
27/2/202414:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
27/2/202413:29EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202412:51EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202412:44EDGAR2Form 8-K - Current report
27/2/202412:30GLOBESpringWorks Therapeutics Reports Fourth Quarter and Full..
22/2/202413:00GLOBESpringWorks Therapeutics to Present at Upcoming Investor..
21/2/202400:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202419:09EDGAR2Form 144 - Report of proposed sale of securities
14/2/202414:56EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202403:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202403:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:38EDGAR2Form 144 - Report of proposed sale of securities
02/2/202422:01EDGAR2Form 8-K - Current report
31/1/202413:00GLOBESpringWorks Therapeutics to Participate in the Guggenheim..
09/1/202403:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202403:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202403:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202403:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202403:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202403:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202412:30GLOBESpringWorks Therapeutics Highlights 2023 Accomplishments and..
21/12/202313:00GLOBESpringWorks Therapeutics to Present at the 42nd Annual J.P...
08/12/202322:05GLOBESpringWorks Therapeutics Announces Closing of Upsized Public..
06/12/202322:10EDGAR2Form 8-K - Current report
06/12/202322:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/12/202306:32GLOBESpringWorks Therapeutics Announces Pricing of Upsized Public..
04/12/202322:19EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/12/202322:13GLOBESpringWorks Therapeutics Announces Proposed Public Offering..
29/11/202313:00GLOBESpringWorks Therapeutics to Participate in the 6th Annual..
28/11/202315:00EDGAR2Form 8-K - Current report
28/11/202313:53DJNSpringWorks Shares Rise on FDA Approval for Tumor Treatment
28/11/202300:46DJNSpringWorks Gets FDA Approval for Desmoid Tumor Treatment
28/11/202300:04GLOBESpringWorks Therapeutics Announces FDA Approval of OGSIVEO™..
17/11/202313:00EDGAR2Form 8-K - Current report
16/11/202312:30GLOBESpringWorks Therapeutics Announces Positive Topline Results..
03/11/202302:02EDGAR2Form 144 - Report of proposed sale of securities
02/11/202312:54EDGAR2Form S-3ASR - Automatic shelf registration statement of..
02/11/202311:38EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202311:35EDGAR2Form 8-K - Current report
02/11/202311:30GLOBESpringWorks Therapeutics Reports Third Quarter 2023..
01/11/202311:30GLOBESpringWorks Therapeutics Announces Presentation of..
04/10/202322:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/9/202322:37EDGAR2Form 3 - Initial statement of beneficial ownership of..

Dernières Valeurs Consultées

NASDAQ
SWTX
SpringWorks Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés